ARRY - Array BioPharma Inc.
| Previous Close | 14.44 |
| Open | 14.36 |
| Bid | 14.02 x 200 |
| Ask | 14.35 x 900 |
| Day's Range | 14.09 - 14.65 |
| 52 Week Range | 6.73 - 18.78 |
| Volume | 2,094,283 |
| Avg. Volume | 3,629,984 |
| Market Cap | 2.926B |
| Beta | 2.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.77 |
| Earnings Date | May 8, 2018 - May 14, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.38 |
Markit•6 days agoSee what the IHS Markit Score report has to say about Array Biopharma Inc.
Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.
- ACCESSWIRE•9 days ago
Today’s Research Reports on Trending Tickers: Array BioPharma and BioMarin Pharmaceutical
NEW YORK, NY / ACCESSWIRE / April 13, 2018 / U.S. markets jumped Thursday as investor’s attention shifted from current geopolitical tensions to the upcoming earnings season. Bank stocks were the top gainers ...
- Simply Wall St.•19 days ago
Is There An Opportunity With Array BioPharma Inc’s (NASDAQ:ARRY) 32% Undervaluation?
In this article I am going to calculate the intrinsic value of Array BioPharma Inc (NASDAQ:ARRY) using the discounted cash flows (DCF) model. Anyone interested in learning a bit moreRead More...
- ACCESSWIRE•27 days ago
Today’s Research Reports on Trending Tickers: Geron Corporation and Array BioPharma Inc.
NEW YORK, NY / ACCESSWIRE / March 26, 2018 / Rising concerns over a potential trade war with China continued to drag markets down on Friday, with the Dow Jones plummeting more than 400 points. The Dow ...
- PR Newswire•last month
Array BioPharma Announces Publication of Detailed Phase 3 COLUMBUS Trial Data of Encorafenib and Binimetinib in Melanoma Patients in The Lancet Oncology
- Trial Demonstrated a Median Progression-Free Survival of 14.9 Months Using Encorafenib and Binimetinib Combination - BOULDER, Colo. , March 22, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) ...
Markit•last monthSee what the IHS Markit Score report has to say about Array Biopharma Inc.
Array Biopharma Inc NASDAQ NMS:ARRY
- PR Newswire•2 months ago
Array BioPharma To Present At The Cowen 38th Annual Healthcare Conference
BOULDER, Colo. , March 5, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the Cowen 38 th Annual Healthcare Conference ...
Markit•2 months agoSee what the IHS Markit Score report has to say about Array Biopharma Inc.
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on January 24. Over the last one-month, outflows of investor capital in ETFs holding ARRY totaled $268 million.
- Investopedia•2 months ago
A Six-Pack of Biotech Bets
Three MoneyShow.com contributors each offer two of their best current ideas in the biotech space.
- GlobeNewswire•2 months ago
New Research Coverage Highlights Timken Steel, National Health Investors, Donaldson, Array BioPharma, Impax Laboratories, and Baxter International — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Feb. 21, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Timken ...
Markit•2 months agoSee what the IHS Markit Score report has to say about Array Biopharma Inc.
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on January 24. Index (PMI) data, output in the Healthcare sector is rising.
- Zacks•2 months ago
Options Traders Expect Huge Moves in Array BioPharma (ARRY) Stock
Array BioPharma (ARRY) needs investors to pay close attention to the stock based on moves in the options market lately.
- Zacks•2 months ago
Zacks.com highlights: Cinemark Holdings, Hasbro, Enova International, Array BioPharma and TechTarget
Zacks.com highlights: Cinemark Holdings, Hasbro, Enova International, Array BioPharma and TechTarget
- Motley Fool•2 months ago
3 Biotech Stocks That Soared This Week: Are They Buys?
It wasn't easy to do in the midst of a market meltdown, but these biotech stocks generated strong gains this week.
- ACCESSWIRE•2 months ago
Today’s Research Reports on Stocks to Watch: Array BioPharma Inc. and Seattle Genetics
NEW YORK, NY / ACCESSWIRE / February 8, 2018 / Array BioPharma has been on fire all week after announcing encouraging data results and strong earnings for its second quarter. Shares of Seattle Genetics ...
- ACCESSWIRE•2 months ago
Wired News – Compugen Reports Publication of Discovery and Validation of ILDR2 as A Novel Immune Checkpoint and Its Use for Auto-Immune Diseases
Stock Monitor: Array BioPharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 08, 2018 / Active-Investors.com has just released a free research report on Compugen Ltd (NASDAQ: CGEN ). If you ...
- PR Newswire•2 months ago
Array BioPharma To Present At The LEERINK Partners 7th Annual Global Healthcare Conference
BOULDER, Colo. , Feb. 7, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the LEERINK Partners 7 th Annual Global Healthcare ...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of ARRY earnings conference call or presentation 6-Feb-18 2:00pm GMT
Q2 2018 Array Biopharma Inc Earnings Call
- MarketWatch•2 months ago
Harry Boxer’s three stocks breaking out on earnings news
In focus: Array BioPharma, Fortinet and Lumentum Holdings.
- Zacks•2 months ago
Array's Melanoma Combo Shows Positive Overall Survival Data
Array's (ARRY) shares gain on impressive overall survival data from a phase III trial of combined binimetinib and encorafenib for BRAF-mutant advanced, unresectable or metastatic melanoma.
- Motley Fool•2 months ago
Here's Why Array BioPharma Inc. Is Rising Today
The combination of better-than-expected quarterly results and upbeat clinical results put traders in a good mood.
- Simply Wall St.•2 months ago
Does Array BioPharma Inc’s (NASDAQ:ARRY) Debt Level Pose A Problem?
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Array BioPharma Inc (NASDAQ:ARRY), with a market capitalization of $2.93B, rarely draw their attention from the investingRead More...
- Reuters•2 months ago
Array melanoma drugs show significant survival vs Roche drug in study
A combination of experimental drugs from Array BioPharma Inc kept patients with advanced melanoma associated with a common gene mutation alive for nearly three years and twice as long as a rival Roche Holding AG medicine, according to data from a late stage study released on Tuesday. The oral drugs, encorafenib and binimetinib, are awaiting a U.S. approval decision by June 30 based on promising data on their ability to stall disease worsening, or progression-free survival (PFS). The Array combination - 450 milligrams of encorafenib once daily and 45 mg of binimetinib twice a day - led to median overall survival of 33.6 months in patients with advanced melanoma with a BRAF mutation, meaning half the patients were still alive nearly three years after treatment.
- Associated Press•2 months ago
Array BioPharma reports 2Q loss
The Boulder, Colorado-based company said it had a loss of 17 cents per share. The results exceeded Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research ...
- PR Newswire•2 months ago
Array BioPharma Reports Financial Results For The Second Quarter of Fiscal 2018
- Encorafenib and binimetinib combination achieved a median overall survival (mOS) of 33.6 months in patients with BRAF-mutant melanoma in Phase 3 COLUMBUS trial - - FDA target action date under PDUFA ...
